Overview

BARDA Securing Anthrax Immunity For the Elderly

Status:
Completed

Trial end date:
2019-12-09

Target enrollment:

Participant gender:

Summary

This study is designed to assess the safety and ability of BioThrax and AV7909 anthrax vaccines to generate an immune response in adults ≥ 66 years of age in stable health in comparison to adults 18-50 years of age in stable health.

Phase:

Phase 2

Details

Lead Sponsor:

Biomedical Advanced Research and Development Authority

Collaborator:

Rho, Inc.

Treatments:

Vaccines